ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2289

Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study

Benjamin Zuckerman1, Alasdair Warwick2, art Schuermans3, Mark Gibson4, Ioasaf Karafotias5, Zijing Yang1, Carine moezinia6, Mark Russell7, Chris Wincup8, James Galloway9 and Sizheng Zhao10, 1King's College London, London, England, United Kingdom, 2University college London, London, United Kingdom, 3KU Leuven, Leuven, Belgium, 4King's College London, Newmarket, United Kingdom, 5King's College London, London, United Kingdom, 6univerity college hospital, London, United Kingdom, 7King's College London, London, United Kingdom, 8King's College Hospital, London, United Kingdom, 9Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 10Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Genome Wide Association Studies, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The pathophysiology of primary Sjögren’s disease involves the interaction of genetic, epigenetic, and environmental factors. With limited treatment options for severe disease, a detailed understanding the proteomic architecture is necessary. Herein, we investigated the associations between circulating proteins on primary Sjögren’s disease using mendelian randomization.

Methods: We selected single nucleotide polymorphisms from protein quantitative trait loci using the genome wide association studies from samples profiled in the UK Biobank Pharma Proteomics Project. Genetic association data for proteins were collected from a study with a sample size of 54,306, and from 3,232 individuals with primary Sjögren’s syndrome and 17,481 controls. Forward and reverse mendelian randomization analyses were conducted. The Wald ratio or inverse variance weighted methods estimated causal effects. We applied colocalization and pleiotropy-robust methods as sensitivity analyses for confounding.

Results: 1,963 of the selected proteins were valid from which 35 survived the mendelian randomization analyses and multiple comparisons assessment, as well as the sensitivity tests (Table 1). Colocalization analyses highlighted that 15 of these proteins had conditional probabilities for a shared causal variant exceeding 80%, suggesting minimal genetic confounding. Notably, our results suggested that CD40 is implicated in primary Sjögren’s disease pathogenesis (odds ratio [OR] 0.80; 95% confidence interval [CI] 0.72-0.88). Reverse mendelian randomization analyses confirmed a causal role for the 15 proteins which survived multiple comparison assessments and identified 28 potential biomarkers for primary Sjögren’s disease (Table 2).

Conclusion: We provided genetic evidence further elucidating the complexity of primary Sjögren’s disease pathogenesis. Additionally, we suggested a genetic causal link between CD40 and primary Sjögren’s disease – supporting the continued investigation of anti-CD40 therapy, such as iscalimab, as a novel treatment for this condition.

Supporting image 1

Table 1. The mendelian randomization results for assessing protein quantitative trait loci association with primary Sjögren’s disease.

Supporting image 2

Table 2. The mendelian randomization results for assessing primary Sjögren’s disease associations with protein quantitative trait loci.


Disclosures: B. Zuckerman: None; A. Warwick: None; a. Schuermans: None; M. Gibson: None; I. Karafotias: None; Z. Yang: None; C. moezinia: None; M. Russell: AbbVie/Abbott, 6, Biogen, 1, Eli Lilly, 6, Galapagos, 6, Menarini, 6, Sandoz, 5, UCB, 6, Viforpharma, 6; C. Wincup: Versus Arthritis, Lupus UK, Astrazeneca and British Society for Rheumatology, 5; J. Galloway: AbbVie, 6, AstraZeneca, 5, Galapagos, 2, 6, Janssen, 2, 5, 6, Lilly, 2, 6, Pfizer, 2, 5, 6, UCB, 6; S. Zhao: None.

To cite this abstract in AMA style:

Zuckerman B, Warwick A, Schuermans a, Gibson M, Karafotias I, Yang Z, moezinia C, Russell M, Wincup C, Galloway J, Zhao S. Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/associations-between-protein-quantitative-trait-loci-and-risk-of-primary-sjogrens-syndrome-a-mendelian-randomization-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-protein-quantitative-trait-loci-and-risk-of-primary-sjogrens-syndrome-a-mendelian-randomization-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology